In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Charles Ruban, CEO at Verdot.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Charles, covering:
Crossing the border from supply chain to R&D, lessons learnt from a technician turned business leader
Creating the most extensive peanut allergy clinical trial in the world and opting for an IPO instead of a big pharma licensing deal
How a call from a PE firm led to a spectacular exit
Designing and creating downstream bioprocessing equipment in a Patagonia-inspired – intelligent, sustainable, and functional way – is critical for the future
Why you need to know several biopharma trends, including AI, China R&D, and the fastest-growing therapeutic segment… you need to know
Over the last 25 years, Charles has held rich and diverse executive leadership positions in fast-growing international healthcare companies. His experience includes Manufacturing, Research and development, Business development, and Global Management in biotechnology and biopharmaceutical companies.
He has been instrumental in streamlining supply chain operations, establishing strategic alliances, developing and launching therapeutic biologics in Europe, the United States, and Japan, and performing business activities. He has been heavily exposed to investors in both public and private environments.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.